Recently, Supreme Court Justice Samuel Alito put a temporary hold on changes affecting how the abortion pill mifepristone can be prescribed. This decision allows patients nationwide to access the medication, primarily used for early medication abortions in the U.S.
Earlier, an appeals court ruled that the Food and Drug Administration (FDA) should revert to rules requiring in-person prescriptions for mifepristone. This change would have banned telehealth options and mailing the medication. Fortunately, Alito’s order restores telehealth access for another week while the legal matter unfolds.
This case is part of a legal challenge from Louisiana, which argues that allowing telemedicine access undermines its strict abortion laws. Louisiana’s position is that telehealth options lead to increased access to abortion, contrary to their goals of restricting it.
Over the past four years since the Supreme Court overturned Roe v. Wade, telemedicine for abortions has surged. Despite various state bans, the number of abortions is reportedly on the rise. Data from the Guttmacher Institute indicates that around 1.1 million abortions involving clinicians occurred in 2025, rising from about 620,000 in 2020, just before the Roe decision.
By 2022, nearly two-thirds of all abortions performed in the U.S. were medication abortions, with around one in four conducted via telehealth. This surge highlights how telemedicine has become a crucial option for many seeking abortion services, especially in restrictive states.
Experts agree that mifepristone is a safe option; over 7 million patients in the U.S. have used it since its approval in 2000. Along with another medication called misoprostol, it is typically used to terminate pregnancies of up to 10 weeks.
A recent ruling from the 5th Circuit Court of Appeals in New Orleans emphasized this tension between federal regulations and state laws. Judge Stuart Kyle Duncan, who authored the ruling, asserted that allowing telemedicine for mifepristone harms Louisiana by undermining its laws and increasing state healthcare costs for emergency situations arising from the drug’s use.
In response to Duncan’s ruling, the manufacturers of mifepristone quickly sought emergency relief from the Supreme Court. Alito’s decision means that the appeals court’s ruling is on hold until next Monday, giving stakeholders time to provide their inputs.
This complex situation reflects broader societal debates on women’s rights and healthcare access. As opinions and laws continue to evolve, it remains clear that mifepristone plays a significant role in reproductive health across the country.
